Please login to the form below

Not currently logged in
Email:
Password:

Rubius Therapeutics poaches Novartis’ Spencer Fisk

He joins the US biotech as its senior VP manufacturing

Novartis’ former vice president and global head of cell and gene technical development and manufacturing Spencer Fisk has decided to join Rubius Therapeutics.

He takes up its senior vice president of manufacturing role as the company is looking to expand its manufacturing and development organisations.

Torben Straight Nissen, president of Rubius Therapeutics, said: “Spencer’s expertise and decades of experience in process development and manufacturing will be invaluable and I look forward to working closely together as we continue to deliver on the promise of the next generation of cellular therapies for patients in need.”

Prior to his new role, Fisk spent the last six years at Novartis where he led the CMC development-manufacturing organisation to deliver the CAR-T portfolio of the company.

He has also held a series of leadership positions for both Merck and Schering Plough.

Fish said: “Rubius is developing an entirely new class of ready-to-use cell therapeutics to treat cancer, autoimmune disorders and rare diseases.

“I look forward to leveraging the expertise i've gained while working with larger pharmaceutical companies to help Rubius take its extraordinary RTC pipeline into the clinic.”

6th March 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics